Using genome-wide data from 253,288 individuals, we identified 697 variants at genome-wide
significance that together explained one-fifth of the heritability for adult height. By testing …

A series of 6- and 7-acrylamide derivatives of the 4-(phenylamino)quinazoline and -pyridopyrimidine
classes of epidermal growth factor receptor (EGFR) inhibitors were prepared from …

There are an estimated 14,000 randomized trials published in chronic kidney disease. The
most frequently reported outcomes are biochemical endpoints, rather than clinical and patient…

4-Anilinoquinazoline- and 4-anilinopyrido[3,4-d]pyrimidine-6-acrylamides are potent pan-erbB
tyrosine kinase inactivators, and one example (CI-1033) is in clinical trial. A series of …

A new route to N-1-substituted pyrazolo- and pyrroloquinazolines has been developed from
the known quinazolones 19 and 23, via conversion to the corresponding thiones, S-…

Genetic alterations in PI3K (phosphoinositide 3-kinase) signalling are common in cancer and
include deletions in PTEN (phosphatase and tensin homologue deleted on chromosome …

Conventional Photodynamic Therapy (PDT) is a well-established treatment for cutaneous
cancers 1 such as basal cell carcinoma (BCC), squamous cell carcinoma-in-situ (SCCis) and …

A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate
the epidermal growth factor receptor tyrosine kinase through specific, covalent modification …

The value of genome-wide over targeted driver analyses for predicting clinical outcomes of
cancer patients is debated. Here, we report the whole-genome sequencing of 485 chronic …

The 4-[(3-bromophenyl)amino]pyrido[3,4-d]pyrimidine PD 158780 is a very potent in vitro
inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) (IC 50 …